|
WO1999046392A1
(en)
*
|
1998-03-12 |
1999-09-16 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods and compositions of chemokine-tumor antigen fusion proteins as cancer vaccines
|
|
IL150961A0
(en)
|
2000-02-04 |
2003-02-12 |
Univ Duke |
Human immunodeficiency virus vaccine
|
|
AU2001254567A1
(en)
*
|
2000-05-02 |
2001-11-12 |
Simon Fraser University |
Polypeptides for use as a vaccine and/or treatment for hiv infection
|
|
US20030228320A1
(en)
*
|
2000-08-18 |
2003-12-11 |
Ashdown Martin Leonard |
Retroviral immunotherapy
|
|
AUPS065002A0
(en)
|
2002-02-20 |
2002-03-14 |
Immunaid Pty Ltd |
Strategy for retroviral immunotherapy
|
|
AU2001291050A1
(en)
|
2000-09-15 |
2002-03-26 |
The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Viral chemokine-tumur antigen fusion proteins
|
|
WO2002022686A2
(en)
|
2000-09-15 |
2002-03-21 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health, Office Of Technology Transfer |
Defensin-antigen fusion proteins
|
|
US20060116325A1
(en)
*
|
2001-02-15 |
2006-06-01 |
Oleg Chertov |
Methods and compositions for inhibiting hiv-coreceptor interactions
|
|
AUPS054702A0
(en)
*
|
2002-02-14 |
2002-03-07 |
Immunaid Pty Ltd |
Cancer therapy
|
|
ES2416629T3
(es)
*
|
2002-12-03 |
2013-08-02 |
University Of Massachusetts |
Vacunas polivalentes de ADN de glicoproteína de VIH-1 primaria y procedimientos de vacunación
|
|
WO2004110384A2
(en)
*
|
2003-06-12 |
2004-12-23 |
Vaxgen, Inc. |
Hiv-1 envelope glycoproteins having unusual disulfide structure
|
|
US8076060B2
(en)
*
|
2003-08-04 |
2011-12-13 |
Emil William Chynn |
Vaccination and immunotherapy as new therapeutic modalities in the treatment of glaucoma
|
|
PT1692516E
(pt)
|
2003-10-24 |
2011-03-07 |
Immunaid Pty Ltd |
Método de terapia
|
|
US20080248022A1
(en)
*
|
2004-09-08 |
2008-10-09 |
Immunaid Pty Ltd |
Therapeutic Strategy for Treating Autoimmune and Degenerative Diseases
|
|
PL1794327T3
(pl)
*
|
2004-09-14 |
2017-04-28 |
Argos Therapeutics, Inc. |
Niezależna od szczepu amplifikacja patogenów i szczepionki przeciwko nim
|
|
WO2007035930A2
(en)
*
|
2005-09-22 |
2007-03-29 |
Prosci Incorporated |
Glycosylated polypeptides produced in yeast mutants and methods of use thereof
|
|
US8221981B2
(en)
*
|
2007-07-30 |
2012-07-17 |
Argos Therapeutics, Inc. |
Primers and probes for the amplification and detection of HIV Gag, Rev and Nef polynucleotides
|
|
AU2009259964B2
(en)
|
2008-06-19 |
2015-04-09 |
Variation Biotechnologies, Inc. |
Compositions and methods for treating influenza
|
|
AU2010251880B2
(en)
|
2009-05-27 |
2015-07-30 |
Biotempus Pty Ltd |
Methods of treating diseases
|
|
WO2011005772A1
(en)
|
2009-07-06 |
2011-01-13 |
Variation Biotechnologies, Inc. |
Methods for preparing vesicles and formulations produced therefrom
|
|
ES2573427T3
(es)
|
2009-07-06 |
2016-06-07 |
Variation Biotechnologies Inc. |
Procedimientos para preparar vesículas y formulaciones producidas a partir de las mismas
|
|
AU2011230619C1
(en)
|
2010-03-25 |
2016-06-23 |
Oregon Health & Science University |
CMV glycoproteins and recombinant vectors
|
|
CA2840079C
(en)
|
2010-07-06 |
2018-07-03 |
Variation Biotechnologies Inc. |
Compositions and methods for treating influenza
|
|
WO2012097346A1
(en)
|
2011-01-13 |
2012-07-19 |
Variation Biotechnologies, Inc. |
Compositions and methods for treating viral infections
|
|
HRP20180607T1
(hr)
|
2011-06-10 |
2019-04-05 |
Oregon Health & Science University |
Glikoproteini i rekombinantni vektori cmv
|
|
CA2789539A1
(en)
|
2011-09-12 |
2013-03-12 |
International Aids Vaccine Initiative |
Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
|
|
US9402894B2
(en)
|
2011-10-27 |
2016-08-02 |
International Aids Vaccine Initiative |
Viral particles derived from an enveloped virus
|
|
CA2894442C
(en)
|
2012-01-12 |
2020-01-21 |
Variation Biotechnologies Inc. |
Compositions and methods for treating viral infections
|
|
US20150079077A1
(en)
|
2012-01-27 |
2015-03-19 |
Variation Biotechnologies, Inc. |
Methods and compositions for therapeutic agents
|
|
EP2679596B1
(en)
|
2012-06-27 |
2017-04-12 |
International Aids Vaccine Initiative |
HIV-1 env glycoprotein variant
|
|
US9951106B2
(en)
|
2012-12-04 |
2018-04-24 |
University Of Maryland, Baltimore |
Recombinant fusion protein comprising HIV gp120 linked to an enhancing CD4 binding site mAb
|
|
EP2848937A1
(en)
|
2013-09-05 |
2015-03-18 |
International Aids Vaccine Initiative |
Methods of identifying novel HIV-1 immunogens
|
|
EP2873423B1
(en)
|
2013-10-07 |
2017-05-31 |
International Aids Vaccine Initiative |
Soluble hiv-1 envelope glycoprotein trimers
|
|
EP3069730A3
(en)
|
2015-03-20 |
2017-03-15 |
International Aids Vaccine Initiative |
Soluble hiv-1 envelope glycoprotein trimers
|
|
EP3072901A1
(en)
|
2015-03-23 |
2016-09-28 |
International Aids Vaccine Initiative |
Soluble hiv-1 envelope glycoprotein trimers
|